Werewolf Therapeutics merges with Ambros in all-stock deal, raises $150M
Werewolf Therapeutics and Ambros Therapeutics agreed to combine in an all-stock merger, alongside an oversubscribed $150 million private placement, to advance Ambros's neridronate program for CRPS-1. The setup shifts HOWL toward a newly financed, single-program clinical story, with deal terms, dilution and development execution becoming the key trading variables.
STOCK PHOTO · DYLAN CHANThe story
The companies announced the definitive agreement on August 21, 2026. The transaction is structured as an all-stock combination, and the post-merger company is expected to operate as Ambros Therapeutics from San Diego while focusing on neridronate development in Complex Regional Pain Syndrome Type 1, also known as Reflex Sympathetic Dystrophy.
The concurrent private placement is described as oversubscribed and totals $150 million. That financing supplies capital around the merger. The next trading catalysts are the detailed merger documents, closing conditions and the financing terms. Clinical milestones for the neridronate program will also determine whether the newly combined company can convert the capital raise into evidence of progress.
Our read · Fri, Aug 21
The merger and $150 million financing give HOWL a funded path into neridronate development, but the all-stock structure leaves dilution and single-program execution as the central risks.
Why. The financing improves the combined company's ability to advance neridronate, while the all-stock consideration makes the ultimate effect on HOWL holders dependent on the undisclosed ownership and issuance terms. With no clinical efficacy data or development timeline in the announcement, the near-term read is balanced between stronger funding and unquantified dilution and execution risk.
Both cases
What could change this view: The trade weakens if the merger documents show substantial dilution or unfavorable ownership terms, or if the neridronate program lacks a clear clinical path after closing.
Who reported it · 1
Keep reading
Latest on the Wire
Australia’s jobless rate hits 5-year high, markets ramp up rate-cut bets for 2027Trump meets Putin and Xi separately ahead of historic three-way talksHyperscale Data warns of $74.8 million gap for Michigan AI projectAlibaba aided China military-linked lab with AI computing technologyMeta pauses plan to give Zuckerberg new shares without losing controlContinue on the Wire →Latest on the Wire
Meta pauses plan to give Zuckerberg new shares without losing controlFed releases October meeting minutes three weeks after policy decisionXi gives Trump a rare hug at Shenzhen airport as US-China tone softensLagarde says she will leave ECB early to counter election misinformationContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAnthropic Said to Guide IPO Pricing Above Market RangeAbout this report
Reported by GlobeNewswire as Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →